Mammalian Transient Protein Expression Market Analysis

End-user (Contract Research Organizations, Biopharmaceutical Companies, Academic & Research Institutes) 

The global mammalian transient protein expression market is segmented and analyzed for demand and supply by end user into contract research organizations, biopharmaceutical companies, and academic & research institutes. Out of these types of segments, the contract research organizations segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising investments in R&D activities to continuously bring up more feasible solutions across the healthcare sector. According to research reports, global research and development spending has more than tripled in real terms since 2000, rising from approximately USD 680 billion to over USD 2.5 trillion in 2019. Besides, the increasing demand for biological products, including vaccines, antibodies, and therapeutic proteins, and growing investment in the drug development sector is further expected to drive the market’s growth.

Application (Bio-production, Functional Cell-Based Assays, Academic Research)

The global mammalian transient protein expression market is also segmented and analyzed for demand and supply by application into bio-production, functional cell-based assays, academic research, and others. Amongst these segments, the bio-production segment is expected to garner a significant share. The growth of the segment can be ascribed to the higher demand for therapeutic proteins, coupled with the surging adoption of protein expression technology for the treatment of millions of patients. For instance, more than 95 genuine and modified therapeutic proteins are approved by the European Union for clinical use. Therapeutic proteins that are based on glycosylation are generally generated by the mammalian cell lines for biological activities. 

Our in-depth analysis of the global market includes the following segments: